Evidence map›Paper›PMID 38132181›Full record

ArticleAntimicrobial agents and chemotherapy2024

The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.

Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, Stefanie Krug, Darla Quijada, Andrew Garcia, Samuel Ayeh, Addis Yilma, Diego L Costa, Alan Sher and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Jennie Ruelas CastilloCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-4570-205X
Pranita NeupaneCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Styliani KaranikaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stefanie KrugCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Darla QuijadaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Andrew GarciaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Samuel AyehCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Addis YilmaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Diego L CostaDepartmento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Alan SherImmunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Nader FotouhiTB Alliance, New York, New York, USA.
Natalya SerbinaTB Alliance, New York, New York, USA.
Petros C KarakousisCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1338-9206
Johns Hopkins University · USTB Alliance · USNational Institutes of Health · USUniversidade de Ribeirão Preto · BR

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Mentoring in Immunometabolic Dysregulation in TB and TB/HIVK24AI143447 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2019 to 2024
$956k
Mechanisms of a therapeutic DNA vaccine targeting Mycobacterium tuberculosis persistersK08AI174959 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Styliani Karanika · 2024 to 2026
$603k
NCI NIH HHS P30 CA006973NIAID NIH HHS K08 AI174959NIAID NIH HHS K24 AI143447
6 · The paper itself

Abstract

Multidrug-resistant (MDR)

Indexed as

MetalloporphyrinsMycobacterium tuberculosisProtoporphyrinsTuberculosis, Multidrug-ResistantAnimalsAntitubercular AgentsDisease Models, AnimalHeme Oxygenase-1MiceRecurrenceAntitubercular AgentsHeme Oxygenase-1MetalloporphyrinsProtoporphyrinstin mesoporphyrintin protoporphyrin IXchemotherapydrug resistanceheme oxygenase 1host-directed therapiesMycobacterium tuberculosis

Identifiers

PMID38132181
PMCPMC10848751
OpenAlexW4390114540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.